GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Z

Zhejiang Huahai Pharmaceutical Co 600521.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

17.32

-1.65%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥8.59bn

FY2016FY2025

Net income

CN¥266.4m

FY2016FY2025

Free cash flow

−CN¥736.0m

FY2016FY2025

Shareholders' equity

CN¥9.44bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥8.59bnCN¥9.55bnCN¥8.31bnCN¥8.27bnCN¥6.64bnCN¥6.49bnCN¥5.39bnCN¥5.09bnCN¥5.00bnCN¥4.09bn
Gross profitCN¥5.17bnCN¥5.81bnCN¥4.93bnCN¥5.09bnCN¥3.97bnCN¥4.10bnCN¥3.19bnCN¥2.95bnCN¥2.80bnCN¥2.04bn
Research and developmentCN¥1.23bnCN¥986.7mCN¥983.0mCN¥925.5mCN¥942.3mCN¥565.7mCN¥467.4mCN¥396.8mCN¥353.4mCN¥364.0m
Operating incomeCN¥833.5mCN¥1.47bnCN¥1.12bnCN¥1.55bnCN¥868.4mCN¥1.29bnCN¥824.4mCN¥475.2mCN¥791.2mCN¥499.4m
Net incomeCN¥266.4mCN¥1.12bnCN¥830.5mCN¥1.17bnCN¥487.5mCN¥929.8mCN¥569.6mCN¥107.5mCN¥639.2mCN¥500.8m
Diluted earnings per share0.180.780.560.780.340.640.410.080.460.39

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥21.50bnCN¥20.26bnCN¥18.60bnCN¥18.15bnCN¥15.47bnCN¥12.99bnCN¥10.73bnCN¥10.37bnCN¥8.27bnCN¥6.73bn
Cash and short-term investments—CN¥1.60bnCN¥1.44bnCN¥1.51bnCN¥1.88bnCN¥2.21bnCN¥1.50bnCN¥910.8mCN¥691.3mCN¥791.6m
Total liabilitiesCN¥12.05bnCN¥11.24bnCN¥10.35bnCN¥10.41bnCN¥8.69bnCN¥6.27bnCN¥4.95bnCN¥6.16bnCN¥3.21bnCN¥2.15bn
DebtCN¥1.84bnCN¥6.52bnCN¥5.65bnCN¥6.86bnCN¥5.63bnCN¥4.05bnCN¥3.31bnCN¥3.55bnCN¥1.81bnCN¥1.02bn
Shareholders' equityCN¥9.44bnCN¥8.90bnCN¥8.08bnCN¥7.55bnCN¥6.56bnCN¥6.51bnCN¥5.61bnCN¥4.07bnCN¥4.88bnCN¥4.38bn
Shares outstanding1,497m1,435m1,483m1,493m1,421m1,457m1,391m1,432m1,392m1,284m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥1.23bnCN¥2.17bnCN¥2.22bnCN¥1.24bnCN¥938.4mCN¥1.56bnCN¥1.75bnCN¥67.9mCN¥546.2mCN¥433.1m
Capital spending−CN¥1.97bn−CN¥1.85bn−CN¥1.59bn−CN¥2.32bn−CN¥2.43bn−CN¥1.28bn−CN¥794.3m−CN¥1.12bn−CN¥794.5m−CN¥732.9m
Free cash flow−CN¥736.0mCN¥319.3mCN¥624.6m−CN¥1.07bn−CN¥1.50bnCN¥279.0mCN¥959.6m−CN¥1.06bn−CN¥248.3m−CN¥299.8m
Dividends paid−CN¥546.2m−CN¥475.4m−CN¥556.0m−CN¥147.3m−CN¥290.9m−CN¥392.8m−CN¥208.9m−CN¥308.0m−CN¥241.6m−CN¥194.4m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥2.58bnCN¥2.34bnCN¥2.18bnCN¥1.89bnCN¥2.15bnCN¥2.37bnCN¥2.30bnCN¥2.12bn
Gross profitCN¥1.52bnCN¥1.35bnCN¥1.21bnCN¥1.09bnCN¥1.27bnCN¥1.53bnCN¥1.27bnCN¥1.39bn
Operating incomeCN¥519.5mCN¥321.3mCN¥118.1m−CN¥7.3mCN¥151.5mCN¥376.8mCN¥153.8mCN¥359.5m
Net incomeCN¥366.7mCN¥404.2m−CN¥114.0m−CN¥29.1mCN¥112.1mCN¥297.4mCN¥87.7mCN¥282.7m
Diluted earnings per share0.240.27-0.08-0.020.070.200.060.20
Cash from operations———CN¥282.0mCN¥174.0mCN¥195.0m—CN¥579.0m
Capital spending−CN¥276.0m−CN¥446.0m−CN¥781.0m−CN¥414.0m−CN¥384.0m−CN¥385.0m−CN¥719.0m−CN¥345.0m
Free cash flow———−CN¥132.0m−CN¥210.0m−CN¥190.0m—CN¥234.0m
Total assetsCN¥21.95bnCN¥22.22bnCN¥21.50bnCN¥21.15bnCN¥21.27bnCN¥21.50bnCN¥20.26bnCN¥19.56bn
Cash and short-term investments———CN¥1.51bnCN¥1.71bnCN¥2.35bnCN¥1.60bnCN¥1.52bn
DebtCN¥2.37bnCN¥2.24bnCN¥1.84bnCN¥4.30bnCN¥6.49bnCN¥6.90bnCN¥6.50bnCN¥6.91bn
Shareholders' equityCN¥9.78bnCN¥9.85bnCN¥9.44bnCN¥9.51bnCN¥9.91bnCN¥9.78bnCN¥8.90bnCN¥8.79bn

Financial ratios

Data as of 25 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin60.2%60.8%59.4%61.5%59.8%63.2%
Operating margin9.7%15.4%13.5%18.7%13.1%19.8%
Net margin3.1%11.7%10.0%14.1%7.3%14.3%
Return on equity2.8%12.6%10.3%15.5%7.4%14.3%
Return on assets1.2%5.5%4.5%6.4%3.2%7.2%
Free cash flow yield13.4%17.7%16.2%15.0%14.9%12.2%
Revenue growth-10.1%14.9%0.5%24.4%2.4%20.4%
Earnings growth-76.2%34.7%-28.9%139.5%-47.6%63.2%
Current ratio0.96x1.42x1.40x1.65x1.61x2.26x
Debt to equity0.19x0.73x0.69x0.80x0.73x0.60x
Equity ratio43.9%43.9%43.4%41.6%42.4%50.1%
Interest coverage3.57x6.51x4.73x6.91x5.09x9.25x
R&D as a share of sales14.3%10.3%11.8%11.2%14.2%8.7%
Buybacks as a share of market value-4.4%3.2%0.7%-5.0%2.4%-4.7%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue1.3%5.8%9.4%
Operating income-18.6%-8.3%5.4%
Net income-38.9%-22.1%-4.9%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin60.5%60.5%60.8%58.9%
Operating margin12.7%14.3%14.9%14.4%
Net margin7.6%9.7%10.0%10.0%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings95.422.926.227.963.153.038.3133.929.325.3
Price to sales3.02.72.64.04.67.64.02.83.83.1

Dividends and splits

Per share, in the currency the company pays

Paid for 6 years. Last went ex-dividend on 18 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2018
Paid in the year0.100.250.200.240.100.200.1820.152
  • 11-for-10 split · 8 Jun 2020
  • 6-for-5 split · 25 May 2018
  • 13-for-10 split · 6 Jun 2016
  • 13-for-10 split · 17 Apr 2013
  • 6-for-5 split · 10 May 2011
  • 3-for-2 split · 4 May 2010

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.